Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Caryl Mussenden

Gynecology Lanham, MD Medical Doctor

NPI 1265585483 CMS profile 57835

9811 Greenbelt Rd, Suite 104, Lanham, MD 20706

Open in the dashboard

General payments

$3,510

179 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Caryl Mussenden of Lanham, MD is reported in the CMS Open Payments database as having received $3,510 across 179 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $515 28
2022 General $763 41
2021 General $524 31
2020 General $850 39
2019 General $858 40

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Caryl Mussenden
  • Gynecology median
  • Middle half of Gynecology
  • National median

In program year 2025, general payments to Caryl Mussenden were reported at $0. Among 1,279 Gynecology profiles paid that year, the median was $162 and the middle half received between $56 and $501.

Show as a table
Year Caryl Mussenden Gynecology median Middle half National median
2019 $858 $199 $66–$472 $163
2020 $850 $114 $42–$287 $114
2021 $524 $141 $42–$430 $132
2022 $763 $173 $52–$532 $149
2023 $515 $170 $57–$501 $160
2024 $0 $157 $50–$424 $164
2025 $0 $162 $56–$501 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Novo Nordisk Inc $991 56 payments
  2. AbbVie, Inc. $473 24 payments
  3. Amgen Inc. $449 8 payments
  4. Lilly USA, LLC $185 11 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $133 8 payments
  6. Abbott Laboratories $125 6 payments
  7. AstraZeneca Pharmaceuticals LP $124 7 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $113 5 payments
  9. Merck Sharp & Dohme Corporation $101 8 payments
  10. Myovant Sciences Inc. $97 5 payments
  11. Other $719 41 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $3,510 179 payments
Products named General payments · program years 2019–2023
  1. Ozempic $774 43 payments
  2. RYBELSUS $555 36 payments
  3. ORIAHNN $221 11 payments
  4. Repatha $203 6 payments
  5. AIMOVIG $202 6 payments
  6. Tresiba $176 12 payments
  7. MYFEMBREE $163 9 payments
  8. ORILISSA $147 10 payments
  9. TRULICITY $134 8 payments
  10. Kerendia $133 8 payments
  11. Other $2,156 133 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

179 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gynecology in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record